COMPANION ANIMAL ARTHRITIS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Companion Animal Arthritis Market, By Animal Type (Dogs, Cats, Others), By Indication (Osteoarthritis, Other Arthritis), By Treatment (Medication (NSAIDs, Monoclonal Antibodies, Others Medications), Supplements, Other Treatments), By Distribution Channel (Veterinary Hospitals & Clinics, Retail Pharmacies, Online Stores, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global Companion Animal Arthritis Market- Recent Developments

In May, 2023, Zoetis Inc., a leading animal health company, announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs. Librela is the first and only once-monthly, anti-NGF monoclonal antibody treatment for canine OA pain and is approved as safe and effective in providing long-term control of OA pain symptoms in dogs, which can improve their mobility and overall quality of life.

Business Development Activities by the Market Players

In April 2023, RaQualia Pharma Inc., a research-based biotech company, and Vetbiolix SAS, a developer of innovative products for the treatment of diseases affecting pets, have agreed to enter into an option and license agreement (“Agreement”) for RQ-00000010 (“RQ-10”), a 5-HT 4 agonist discovered by RaQualia Pharma, to develop pet pharmaceuticals for the treatment of gut motility disorders in dogs and cats.